Bladder cancer kills 16 people a day in the UK alone — but engineers at the University of Glasgow may have found a way to improve survival by implanting a device no bigger than a coin directly into tumors.
The innovation addresses a fundamental problem with photodynamic therapy, a cancer treatment that uses light-sensitive drugs to selectively destroy malignant cells. While the approach shows real promise, particularly for early-stage cancers, it has long been hampered by the human body's tendency to absorb light, making it difficult for doctors to deliver enough illumination to reach tumors buried deep in organs like the bladder. Current treatments often require invasive surgeries and cumbersome external light sources — burdens that limit both effectiveness and patient comfort.
The team led by Professor David Flynn at Glasgow's James Watt School of Engineering has designed a small, disk-shaped device measuring just 40 millimeters across. Fabricated using laser-based techniques at the university's nanofabrication centre, the implant uses four micro-LEDs mounted on a flexible substrate made of Parylene C, a biocompatible polymer approved for use in medical devices. The breakthrough lies in its wireless power delivery: using resonant inductive coupling, the tiny LEDs can produce optical outputs exceeding five megawatts without requiring any external power source or wiring.
In laboratory testing published in the journal Opto-Electronic Advances, the Glasgow team demonstrated that their device could transmit light with minimal loss through synthetic tissue samples up to 50 millimeters thick — roughly mimicking the depth of real tissue barriers. More importantly, when combined with photosensitizer solutions, the implant reliably generated singlet oxygen, the highly reactive molecule responsible for destroying cancer cells. The results suggest the system could deliver precisely targeted light exactly where it's needed, with far less tissue damage than conventional approaches.
Dr. Rolan Mansour, the paper's corresponding author, frames the stakes plainly: in developed nations, one in three people will develop cancer in their lifetime, and bladder cancer represents a significant portion of that burden. Yet the disease is potentially curable if caught early, before it spreads to adjacent organs. "Our work is focused on improving its effectiveness by delivering light where it's most needed, to the photosensitizers which tackle and kill cancer cells," Mansour said. By replacing invasive external systems with a minimally invasive implant, the approach could reduce patient trauma while improving treatment precision.
The device represents the latest achievement of the EPSRC PATIENT project, which brings together engineers and cancer scientists to reimagine how flexible bioelectronics and wireless power delivery can transform medical treatment. The team's results remain preliminary — the technology has not yet been tested in human patients — but the laboratory evidence is encouraging enough that clinicians are already envisioning its potential application in the coming years.
For bladder cancer patients, the implications could be substantial. A more precise, comfortable, and effective form of photodynamic therapy could mean earlier intervention with fewer side effects, potentially shifting the disease from a serious threat into one that responds reliably to treatment. That prospect alone marks a meaningful step forward in how medicine harnesses light to fight cancer.